Breaking News

Lonza to Build Small Molecule Manufacturing Complex in Visp

Will invest $220 million to construct the complex that will include a manufacturing line for antibody-drug conjugate payload molecules.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lonza, a contract development and manufacturing organization (CDMO) partner to the biopharma industry, is investing CHF 200 million (~$220mn) in the construction of a new small molecule manufacturing complex at its Visp site in Switerland. The new manufacturing complex will occupy an overall footprint of approximately 2000 square meters with six levels of manufacturing space. The complex will offer several opportunities for future expansions supporting the small molecules technologies offering, ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters